Streetbeat News

Products Services

ARVN

Arvinas, Inc. (NASDAQ:ARVN) has announced interim data from its Phase 1/2 clinical trial for bavdegalutamide (ARV-110), a novel PROTAC® protein degrader, at the European Society for Medical Oncology Congress. The company also presented new data from an updated analysis of its ongoing Phase 1/2 clinical trial with its second-generation PROTAC AR degrader, ARV-766, showing clinical activity extending across patients with AR LBD mutations. Arvinas plans to prioritize the initiation of a Phase 3 trial with ARV-766 in mCRPC.

Portfolio Pulse from Charles Gross

October 22, 2023 | 3:28 pm

PSNL

Personalis, Inc. (NASDAQ:PSNL) announced initial findings from its work with the TRACERx lung cancer study, demonstrating a significant advancement in lung cancer circulating tumor DNA (ctDNA) detection and management. The Personalis NeXT Personal cancer assay, designed to detect and monitor residual and recurrent disease (MRD), showed significantly improved detection rates for early-stage lung cancer.

Portfolio Pulse from Charles Gross

October 22, 2023 | 3:25 pm

AGEN

Agenus Inc. (NASDAQ:AGEN) announced expanded data from its phase 1b study of botensilimab and balstilimab in patients with advanced sarcomas. The results showed a 40% 6-month PFS, 20% ORR, and a 63% disease control rate. The median duration of response was 19.4 months.

Portfolio Pulse from Charles Gross

October 22, 2023 | 3:23 pm

STRO

Sutro Biopharma announced initial results from a Phase 1 dose-expansion study of luveltamab tazevibulin (luvelta), a novel Folate receptor alpha (FolRα)-targeting ADC, in patients with endometrial cancer. The study showed encouraging preliminary anti-tumor activity in patients with FolRα-expressing endometrial cancer. In patients with TPS >25% FolRα expression, a confirmed partial response was seen in 29% of cases, and the Disease Control Rate was 86%.

Portfolio Pulse from Charles Gross

October 22, 2023 | 3:17 pm

JNJ

Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, announced positive results from the Phase 2b SunRISe-1 study of TAR-200 monotherapy for high-risk non-muscle-invasive bladder cancer. The study showed a 77% complete response rate in patients, with sustained responses beyond one year.

Portfolio Pulse from Charles Gross

October 22, 2023 | 3:14 pm

OLMA

Olema Oncology announced the results of a Phase 2 clinical study for Palazestrant, a treatment for metastatic ER+/HER2- breast cancer. The results, presented at the ESMO Congress 2023, showed a median progression-free survival (PFS) of 4.6 months across all patients, and 5.6 months in patients with ESR1 mutations. The results support the continued development of Palazestrant in the OPERA-01 monotherapy Phase 3 pivotal trial.

Portfolio Pulse from Charles Gross

October 22, 2023 | 3:11 pm

RVMD

Revolution Medicines, Inc. (NASDAQ:RVMD) announced promising anti-tumor and safety data for RMC-6236, its RASMULTI(ON) Inhibitor, in patients with previously treated non-small cell lung cancer and pancreatic ductal adenocarcinoma. The drug demonstrated preliminary evidence of clinical activity and an acceptable safety profile across several dose levels and KRASG12X genotypes.

Portfolio Pulse from Charles Gross

October 22, 2023 | 3:06 pm

EXEL

Exelixis, Inc. (NASDAQ:EXEL) announced results from a phase 3 trial of cabozantinib, which showed significant improvements in progression-free survival for patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. The company plans to discuss these results with the U.S. Food and Drug Administration.

Portfolio Pulse from Charles Gross

October 22, 2023 | 2:56 pm

ALPMY

SGEN

Seagen Inc. and Astellas Pharma Inc. announced positive results from the Phase 3 EV-302 clinical trial for PADCEV in combination with KEYTRUDA versus chemotherapy. The combination improved overall survival and progression-free survival in patients with previously untreated locally advanced or metastatic urothelial cancer. The risk of death was reduced by 53% and overall survival improved by more than 15 months compared to chemotherapy. These results will form the basis of global regulatory submissions.

Portfolio Pulse from Charles Gross

October 22, 2023 | 2:48 pm

GMAB

SGEN

Genmab A/S (GMAB) and Seagen Inc. (SGEN) announced additional results from the Phase 3 innovaTV 301 trial, showing that TIVDAK significantly reduced the risk of death in recurrent or metastatic cervical cancer patients compared to chemotherapy. The results were presented at the European Society of Medical Oncology Congress 2023.

Portfolio Pulse from Charles Gross

October 22, 2023 | 2:45 pm